Clinical trial
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to…
NCT00312377 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00312377 |
|---|---|
| Title | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer |
| Official title | A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC |
| Acronym | ZODIAC |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer, Lung Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Vandetanib |
| Enrollment | 1,690 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Mar 1, 2014 |
| First posted | Apr 10, 2006 |
| Last update posted | Sep 30, 2016 |
| Countries | Argentina, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece, India, Indonesia and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: